Reproxalap in patients with seasonal allergic conjunctivitis: a systematic review and meta-analysis.

ABSTRACT:

Introduction

Seasonal allergic conjunctivitis (SAC) is a hypersensitivity condition characterized by itching, tearing, and redness. It affects over 20% of the general population with limited therapeutic options. Reproxalap, a novel small-molecule aldehyde trap, has emerged as a potential treatment option for SAC by targeting reactive aldehydes involved in inflammation. In this systematic review and meta-analysis, we assessed the efficacy and safety of Reproxalap in treating SAC.

Methods

Multiple databases were searched including PubMed, Cochrane Library, Scopus, and Google Scholar, to identify relevant studies. Clinical trials involving patients diagnosed with SAC and treated with Reproxalap (0.25% or 0.5%) were included. The primary outcomes were symptom relief (efficacy) a

SUBMITTER: Elgadi A 

PROVIDER: S-EPMC12037956 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature